Clinical Trial Update: Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating niraparib in combination with bevacizumab for platinum-refractory/resistant recurrent ovarian cancer; efficacy and safety data are not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Neoplasms
• Ovarian Neoplasms

Drugs mentioned

• Bevacizumab (bevacizumab)
• Niraparib (Niraparib)

Snippet

Sponsor: Xiaoxiang Chen | Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Status: UNKNOWN